Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Recruiting now · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

In brief

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Key facts

Study ID

NCT05379985

Run by

Revolution Medicines, Inc.

People needed

754

Starts

2022-05-31

Expected to finish

2027-07-26

Last updated by the study team

2026-05-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
• Treatment naive or have received prior standard therapy appropriate for tumor type and stage
• Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function

You may not qualify if…

• Primary central nervous system (CNS) tumors
• Active, untreated brain metastases
• Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
• History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
• Other inclusion/exclusion criteria may apply.

Where it is running

• UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California, United States (enrolling)
• UCLA — Santa Monica, California, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Piedmont Healthcare — Atlanta, Georgia, United States (enrolling)
• Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana, United States (enrolling)
• Johns Hopkins University — Baltimore, Maryland, United States (enrolling)
• Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Perlmutter Cancer Center at NYU Langone Health — New York, New York, United States (enrolling)
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States (enrolling)
• Columbia University — New York, New York, United States (enrolling)
• Christ Hospital Cancer Center — Cincinnati, Ohio, United States (enrolling)
• Taylor Cancer Research Center — Maumee, Ohio, United States (enrolling)
• Tennessee Oncology — Chattanooga, Tennessee, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• University of Texas at Austin — Austin, Texas, United States (enrolling)
• Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Next Oncology — San Antonio, Texas, United States (enrolling)
• Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
• Next Oncology Virginia — Fairfax, Virginia, United States (enrolling)
• Virginia Mason Medical Center — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.